| Therapeutic antibodies for human diseases at the dawn of the twenty-first century OH Brekke, I Sandlie Nature reviews Drug discovery 2 (1), 52-62, 2003 | 950 | 2003 |
| The neonatal Fc receptor (FcRn): a misnomer? M Pyzik, KMK Sand, JJ Hubbard, JT Andersen, I Sandlie, RS Blumberg Frontiers in immunology 10, 1540, 2019 | 376 | 2019 |
| Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics KMK Sand, M Bern, J Nilsen, HT Noordzij, I Sandlie, JT Andersen Frontiers in immunology 5, 682, 2015 | 329 | 2015 |
| Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential NM Stapleton, JT Andersen, AM Stemerding, SP Bjarnarson, RC Verheul, ... Nature communications 2 (1), 599, 2011 | 304 | 2011 |
| Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells L Norderhaug, T Olafsen, TE Michaelsen, I Sandlie Journal of immunological methods 204 (1), 77-87, 1997 | 244 | 1997 |
| Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8− CD11b+ dendritic cells K Baker, SW Qiao, TT Kuo, VG Aveson, B Platzer, JT Andersen, I Sandlie, ... Proceedings of the National Academy of Sciences 108 (24), 9927-9932, 2011 | 228 | 2011 |
| Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding 2 JT Andersen, MB Daba, G Berntzen, TE Michaelsen, I Sandlie Journal of Biological Chemistry 285 (7), 4826-4836, 2010 | 214 | 2010 |
| The structural requirements for complement activation by IgG: does it hinge on the hinge? OH Brekke, TE Michaelsen, I Sandlie Immunology today 16 (2), 85-90, 1995 | 207 | 1995 |
| Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor JT Andersen, B Dalhus, J Cameron, MB Daba, A Plumridge, L Evans, ... Nature communications 3 (1), 610, 2012 | 206 | 2012 |
| The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery M Bern, KMK Sand, J Nilsen, I Sandlie, JT Andersen Journal of Controlled Release 211, 144-162, 2015 | 201 | 2015 |
| Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation JE Thommesen, TE Michaelsen, GÅ Løset, I Sandlie, OH Brekke Molecular immunology 37 (16), 995-1004, 2000 | 182 | 2000 |
| Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding JT Andersen, B Dalhus, D Viuff, BT Ravn, KS Gunnarsen, A Plumridge, ... Journal of Biological Chemistry 289 (19), 13492-13502, 2014 | 181 | 2014 |
| Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells ST Jung, ST Reddy, TH Kang, MJ Borrok, I Sandlie, PW Tucker, ... Proceedings of the National Academy of Sciences 107 (2), 604-609, 2010 | 176 | 2010 |
| Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry KH Roux, L Strelets, OH Brekke, I Sandlie, TE Michaelsen the Journal of Immunology 161 (8), 4083-4090, 1998 | 155 | 1998 |
| Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies A Shaw, IT Hoffecker, I Smyrlaki, J Rosa, A Grevys, D Bratlie, I Sandlie, ... Nature nanotechnology 14 (2), 184-190, 2019 | 154 | 2019 |
| The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH‐dependent binding to albumin JT Andersen, J Dee Qian, I Sandlie European journal of immunology 36 (11), 3044-3051, 2006 | 146 | 2006 |
| IgG3 antibodies with shortened hinge region and a complement activation test T Michaelsen, I Sandlie US Patent 5,348,876, 1994 | 139 | 1994 |
| The influence of the hinge region length in binding of human IgG to human Fcγ receptors S Redpath, TE Michaelsen, I Sandlie, MR Clark Human immunology 59 (11), 720-727, 1998 | 136 | 1998 |
| The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics JT Andersen, I Sandlie Drug metabolism and pharmacokinetics 24 (4), 318-332, 2009 | 134 | 2009 |
| Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn RF Hallstensen, G Bergseth, S Foss, S Jæger, T Gedde-Dahl, J Holt, ... Immunobiology 220 (4), 452-459, 2015 | 120 | 2015 |
